Quick Facts: Prolat

• Condition Addressed: Moderate to severe pain.
• Therapeutic Role: Management of pain that necessitates an opioid analgesic.
• Use Context: For patients whose pain has not been adequately addressed by or who cannot tolerate alternative non-opioid treatments.

---

What Prolat Treats: Main Uses and Benefits

Prolat is a prescription medication utilized in the management of moderate to severe pain. Its approved therapeutic purpose is to provide relief for pain that is of an intensity requiring an opioid analgesic, particularly in clinical situations where other treatment options, such as non-opioid pain relievers, have not provided a sufficient therapeutic response or are not suitable for the patient.

The use of Prolat contributes to the relief of discomfort associated with the primary condition being managed. As an opioid-containing product, it is reserved for circumstances where the need for this type of agent is clearly established and other approaches are deemed insufficient by a healthcare professional. It is administered as part of a comprehensive pain management strategy.

This medication is a combination product containing both an opioid analgesic component and acetaminophen. The two components work to address the patient's pain experience through different pathways. Patients should consult the prescribing information for comprehensive details on its authorized use in pain management.

Regulatory References

1. DailyMed: Prolat (Oxycodone and Acetaminophen Tablets, USP)

Prolat (Oxycodone and Acetaminophen) is officially reserved for adult patients experiencing moderate to severe pain that necessitates an opioid analgesic and for whom alternative pain management strategies are inadequate or not tolerated. The regulatory profile defines distinct populations for whom use is prohibited or restricted.

Contraindicated Populations

Use of Prolat is strictly contraindicated in patients with known hypersensitivity to oxycodone, acetaminophen, or any component of the product. It must not be administered to individuals experiencing significant respiratory depression or severe bronchial asthma, or those with suspected or known paralytic ileus or gastrointestinal obstruction. Use is also prohibited in patients who have recently taken a Monoamine Oxidase Inhibitor (MAOI).

Restricted and Conditional Use

Safety and effectiveness in pediatric patients are not established. For older adults, caution is required, with initial dosing generally starting low due to increased sensitivity and risk of respiratory depression. Use requires special monitoring in patients with severe hepatic or renal impairment, pre-existing respiratory diseases (like COPD), and conditions causing increased intracranial pressure. Prolonged use during pregnancy is not recommended due to the risk of Neonatal Opioid Withdrawal Syndrome.

Interactions with other medicines and products

Regulatory documentation for Prolat (Oxycodone/Acetaminophen) highlights clinically significant interactions based on two primary mechanisms: pharmacodynamic effects and pharmacokinetic (metabolic) interference.

Pharmacodynamic Interactions

The co-administration of Prolat with other Central Nervous System (CNS) Depressants is officially documented to result in additive effects, potentially leading to profound sedation, respiratory depression, coma, and death. This category includes general anesthetics, tranquilizers, sedative-hypnotics, other opioid analgesics, and Alcohol (Ethanol), which is specifically cited as a high-risk substance. Furthermore, co-administration with Anticholinergics is noted to increase the risk of producing or exacerbating paralytic ileus.

Metabolic Interactions

The oxycodone component is processed by the Cytochrome P450 3A4 (CYP3A4) enzyme. Co-administration with CYP3A4 Inhibitors is officially stated to increase oxycodone plasma concentrations, which may increase adverse effects. Conversely, CYP3A4 Inducers may decrease plasma concentrations. The discontinuation of a CYP3A4 inducer is officially noted to cause a rapid increase in oxycodone concentration. Substances such as Monoamine Oxidase Inhibitors (MAOIs) or Tricyclic Antidepressants may also potentiate the effects of the oxycodone component.

How Prolat Works: Pharmacodynamic Mechanism

Prolat functions as a competitive antagonist primarily at the beta1-adrenergic receptors, which are densely expressed in cardiac tissue. By selectively occupying these receptors, the drug directly dampens the activating influence of endogenous Catecholamines (stress hormones) on the heart muscle, initiating a sympatholytic action. This interference at the cellular level reduces the beta1-mediated activation of the intracellular cAMP signaling cascade, thereby modulating myocardial function.

This molecular blockade translates directly into two major physiological effects: a negative chronotropic effect (slower heart rate) and a negative inotropic effect (reduced force of contraction). This synchronized action results in reduced heart muscle's overall oxygen consumption and diminishes mechanical workload. Furthermore, the drug suppresses Renin release from the kidney by blocking beta1 receptors on juxtaglomerular cells, thereby modulating the Renin-Angiotensin-Aldosterone System (RAAS) and resulting in systemic hemodynamic adjustments that reduce peripheral resistance.

While primarily beta1-selective, this selectivity is dose-dependent and can be overcome at higher plasma concentrations, leading to involvement of beta2 receptors in the bronchial smooth muscle. The core mechanism, by suppressing sympathetic signals, can also prevent the physiological manifestation of sympathetic activation, such as reflex tachycardia, during periods of increased adrenergic drive.

The administration of Prolat (Oxycodone and Acetaminophen) is strictly governed by guidelines defining its use, route, and dosing limits. This medication is available as an oral tablet and an oral solution, intended exclusively for the oral route of administration.

Official Dosing and Frequency

The standard schedule requires the medicine to be taken on an as-needed basis (PRN) for pain, typically at intervals of 4 to 6 hours. Dosing generally starts with one tablet of the prescribed strength, with subsequent adjustment guided solely by the patient's individual pain response. Prolat can be taken with or without food.

Mandatory Use Restrictions

Administration is subject to a strict maximum daily limit for the Acetaminophen component, which must not exceed 4000 mg (4 grams) from all sources in a 24-hour period. Patients must consequently avoid co-administering any other product containing Acetaminophen. For patients using the oral solution, a calibrated measuring device must be utilized to ensure the dose is accurately delivered.

Course Duration and Adjustments

Prolat is intended for short-term management of pain. Dosage modification may be required for patients with severe hepatic or renal impairment. Additionally, older adults may require closer monitoring. If the drug is discontinued following prolonged administration, guidance mandates a gradual dose reduction (tapering) process.

Research Evidence: Overview of Studies for Prolat (Oxycodone and Acetaminophen)

Evidence for Use in Moderate to Severe Acute Pain

The core research examining Prolat's use in pain that is severe and short-term (acute) relies mainly on short-term Randomized Controlled Trials (RCTs) and systematic reviews that pool data from these trials. These trials were primarily conducted in adult populations experiencing moderate to severe pain following procedures such as dental surgery or trauma. Researchers applied these studies to examine outcomes related to physical discomfort.

Studies monitored various metrics, including how symptoms were observed during the short-term periods. Findings describe patterns observed in the studies, particularly regarding measurements on standardized pain scales within the first few hours after a dose. Research highlights that studies examined short-term changes in pain intensity in research contexts involving comparison to a placebo. Trial reports summarized the duration of the analgesic effect for the short-acting formulation, typically focusing on periods up to 4 to 6 hours post-dose.

Overview of Studies for Chronic Pain Management

For the management of chronic non-cancer pain, the research scenarios differ significantly from acute pain studies. Researchers have utilized complex designs, including Enriched Enrollment Randomized Withdrawal (EERW) studies. These trials and observational settings evaluated outcomes related to daily functioning or activity level, alongside the long-term maintenance of analgesia in adults managing pain that may vary in intensity.

Systematic reviews of this body of evidence report data showing patterns related to outcomes reflecting daily functioning over intermediate periods, such as several months. However, trials often experience significant participant dropout over time, which can limit the certainty of the findings regarding long-term consistency.

What the Research Landscape Does Not Yet Characterize

The full picture of long-term outcomes are not fully established by definitive controlled trials, as most extended-duration data comes from observational cohorts. The controlled studies demonstrating short-term effects provide context but not individual predictions; research does not determine whether an individual will respond similarly. Furthermore, comparative evidence is lacking for high-quality, head-to-head trials against all alternative analgesic strategies, and data for certain groups remain insufficient, particularly for older adults and individuals with specific chronic comorbidities.

Key Studies & References

1. Label: OXYCODONE AND ACETAMINOPHEN tablet - DailyMed
2. Effect of a Single Dose of Oral Opioid and Nonopioid Analgesics on Acute Extremity Pain in the Emergency Department: A Randomized Clinical Trial

Common questions about Prolat (FAQ)

---

Q: Can I take this drug if I am pregnant?

Official regulatory documents, such as those provided to the FDA and EMA, contain specific information on Prolat's use during pregnancy. This information includes any established risk classifications or available data from human or animal studies. This detailed information is available to healthcare providers to guide discussion about risks and benefits based on individual circumstances.

---

Q: Is it safe to drive after taking this medicine?

The official product labeling specifically addresses the medication's effects on the ability to drive or operate machinery. If the medicine is known to cause side effects like dizziness or drowsiness, the label advises caution. Reviewing the official product information can help users identify potential risks. Healthcare providers are the best resource for concerns about individual impairment.

---

Q: Does this medicine interact with alcohol?

Official drug information provides details on known or potential interactions between Prolat and alcohol. These warnings describe how concurrent use might increase the risk of certain side effects or lead to other adverse health outcomes. The full product information offers specific details regarding alcohol consumption.

---

Q: How should I store the medicine?

The official product packaging and labeling clearly specify the required storage conditions for Prolat. This includes details like the recommended temperature range and protection from factors such as light or humidity to maintain the medicine's quality and effectiveness.

---

Q: Is it safe to take this drug long-term?

Official product documents define the approved duration of use for the condition Prolat is intended to treat. The labeling also lists adverse reactions observed in clinical trials over various time frames. This information provides the safety basis for the drug's approved use. Healthcare professionals are the resource for discussing individual long-term safety considerations.

---

Q: Can I use this medicine for my migraine headaches?

Regulatory documents explicitly list the approved indications, which are the specific diseases or conditions for which Prolat has been authorized for use by health authorities. Use of the medicine for a condition not listed in the official indications, such as migraine headaches, is considered 'off-label.' The regulatory approval is limited to the therapeutic indications explicitly described in the official product documents.

The official regulatory guidelines for Prolat (Oxycodone and Acetaminophen Tablets, USP) detail specific requirements for storage and disposal, prioritizing product stability and public safety.

Required Storage Conditions

The tablets must be stored at a controlled room temperature between 20°C and 25°C (68°F and 77°F). The container must be a tight, light-resistant container and must be kept tightly closed to protect the contents from both moisture and excessive heat. All medication must be kept out of the sight and reach of children and stored in a secure location, as it is a controlled substance.

Official Disposal Instructions

Unused or expired Prolat should be disposed of promptly. The preferred method is to use a drug take-back program. If one is unavailable, the U.S. Food and Drug Administration (FDA) recommends immediately flushing the tablets down the toilet to prevent accidental ingestion, which is deemed a higher risk than environmental concerns.